Share on StockTwits

Recro Pharma’s (NASDAQ:REPH) lock-up period will end on Wednesday, September 3rd. Recro Pharma had issued 3,750,000 shares in its initial public offering on March 7th, AmericanBankingNews.com reports. The total size of the offering was $30,000,000 based on an initial share price of $8.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Separately, analysts at Aegis initiated coverage on shares of Recro Pharma in a research note on Thursday, June 12th. They set a “buy” rating and a $40.00 price target on the stock.

Shares of Recro Pharma (NASDAQ:REPH) traded down 3.89% on Tuesday, hitting $5.69. The stock had a trading volume of 10,403 shares. Recro Pharma has a one year low of $5.01 and a one year high of $9.88. The stock’s 50-day moving average is $6.01 and its 200-day moving average is $6.79. The company’s market cap is $43.9 million.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.25) by $0.11. On average, analysts predict that Recro Pharma will post $-2.96 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.